Studies published in Science report On June 30, evidence was presented that silosbin mushrooms have a significant impact on participants’ mood and mental health.
The study“Psilocybin microdosers observed improved mood and mental health in one month compared to non-microdosing controls,” analyzed 1,133 subjects between November 2019 and May 2021. Did. After 22-35 days.
Researchers analyzed the results of silosibine microdosing in combination with one of the lion’s mane mushrooms (Lion’s maneOr HE) or niacin (vitamin B3), “a small to medium-scale improvement in mood and mental health that was generally consistent throughout the presence of gender, age, and mental health concerns … a particular spirit Improving athletic performance For older people. ”In this study, these combinations are called“ stacking ”.
The study summary states that the combination of psilocybin with HE or B3 “did not affect changes in mood or mental health,” but older participants were either psilocybin alone or psilocybin and HE. I experienced an improvement in psychomotor.
This study was written by a number of authors, including Paul Stamets and Joseph M. Rootman, Faculty of Psychology, University of British Columbia.According to an interview with ForbesRootman is confident that the work being done now will help lead to more revelation in the future. “This study is an extension of a previous manuscript published in the same journal, and there are additional publications in preparation based on this same study,” says Rootman. “Our team has also been working hard over the next few years to develop the next version of the study used to generate findings related to psychedelic microdosing.”
Rootman also found that the study did not require just one mushroom variety. Rather, the researchers simply observed the patient’s recorded experience. This ranged from small, medium, or large amounts of mushrooms (0.1 grams, 0.1-0.3 grams, or 0.3 grams or more, respectively). “We found that about 10% of the microdosing samples in this study reported high doses, 72.6% reported medium doses, and 16.8% reported low doses,” Rootman added.
The study description shares the author’s collective belief that this is one of the first studies of this kind, but to lay the foundation for how psilocybin can help human participants. Needs more research. “To better understand the health effects of this new phenomenon, further studies with controls and large samples that allow investigation of potential moderators such as mental health status, age, and gender. Is needed, “the author concludes. “This study extends this literature by examining the expected changes associated with microdosing psilocybin in the areas of mental health, mood, cognitive and psychomotor function compared to controls other than microdosing. As far as we know, this is the largest prospective study of microdosing psilocybin to date, first distinguishing microdosing mixtures (ie stacking) and according to age and mental health concerns. It is one of the few prospective studies that systematically decomposes analysis. “
Gradually, more evidence is being gathered in such studies. But it’s still not enough to convince people who oppose the use of medical psilocybin. At the end of June, Linn County, Oregon announced approval of a voter initiative to ban psilocybin therapy and treatment centers (other parts of the state have adopted a voter-approved psilocybin therapy program scheduled to begin in 2023. I plan to do it).
Earlier last month, a South African-based study found that psilocybin helps treat women with HIV and depression. Another April study also found that psilocybin has potential as a treatment for depression. In May, activists from the Right to Try organization recently protested outside Virginia’s Drug Enforcement Headquarters to pay attention to patients who could use psilocybin to improve their quality of life.